Physician profile
Faran Bashir
NPI 1316944721
$20,351.83
in general payments reported to CMS, 2019-2025
41 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,874 · 2020: $7,295 · 2021: $3,726 · 2022: $1,371 · 2023: $2,476 · 2024: $2,059 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,085.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $7,969.92 | 2019-2024 | Farxiga |
| Abbott Laboratories | $4,166.30 | 2019-2025 | Assurity, Gallant, Cardiomems |
| Novartis Pharmaceuticals Corporation | $1,140.69 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $940.25 | 2019-2025 | Lifevest |
| Medtronic, INC. | $940.14 | 2021-2024 | Micra, Azure Xt Dr Mri Surescan |
| Boston Scientific Corporation | $574.57 | 2019-2023 | Watchman Access System |
| Atricure, INC. | $451.80 | 2023-2024 | |
| Medtronic Vascular, INC. | $450.61 | 2019-2020 | |
| Heartflow, INC. | $361.95 | 2019-2024 | Ffrct |
| Pfizer INC. | $291.25 | 2019-2025 | |
| Abiomed | $204.00 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $202.52 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $202.01 | 2019-2023 | Xarelto |
| Philips North America LLC | $189.37 | 2019-2022 | |
| Terumo Medical Corporation | $175.19 | 2019 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $173.66 | 2020-2024 | Orsiro Mission |
| Saranas, INC. | $171.74 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.95 | 2019-2024 | Jardiance |
| Impulse Dynamics (USA) INC. | $150.40 | 2024 | Optimizer |
| Kestra Medical Technology Services, INC. | $121.68 | 2022-2024 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $121.40 | 2022-2023 | |
| Bardy Diagnostics, INC. | $120.00 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $119.75 | 2022 | |
| Astellas Pharma US INC | $118.31 | 2019 | |
| Amgen INC. | $113.12 | 2019-2025 | Repatha, Repatha |
| Cvrx, INC. | $93.75 | 2023 | Barostim Neo System |
| Cleerly, INC. | $89.85 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Daiichi Sankyo INC. | $74.63 | 2023 | Injectafer |
| Novo Nordisk INC | $72.48 | 2024-2025 | Wegovy |
| Edwards Lifesciences Corporation | $64.94 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $50.36 | 2019-2023 | Amvuttra |
| Kiniksa Pharmaceuticals, Ltd. | $42.93 | 2022-2023 | Arcalyst |
| Inspire Medical Systems, INC. | $39.02 | 2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $35.28 | 2025 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $34.72 | 2019-2021 | |
| Akcea Therapeutics, INC. | $27.40 | 2020 | |
| Ekos Corporation | $22.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.72 | 2019 | |
| Recor Medical INC | $19.44 | 2024 | Paradise Renal Denervation System |
| Kiniksa Pharmaceuticals International, Plc | $17.06 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $16.91 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faran Bashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.